Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress

British Journal of Cancer

Volumn 88, Issue 10, 2003, Pages 1649-1658

  Allman, R ^a   Errington, R J ^b   Smith, P J ^b  

^a Velindre NHS Trust   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; Cell cycle; Mitosis; p53; Paclitaxel

Indexed keywords

CYCLIN B1; PACLITAXEL; PROTEIN P53;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CELL MUTANT; CONCENTRATION RESPONSE; DNA DAMAGE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KINETICS; MITOSIS INHIBITION; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MITOSIS; PACLITAXEL; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038792642     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600905     Document Type: Article

References (67)

1. Allman R, Smith PJ (2002) Mitotic Arrest is not Required for Taxol Induced Cell Death. Proceedings of the XXI Congress of the International Society for Analytical Cytology 2002, San Diego, USA
2. Callahan R (1992) P53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84: 826-827
3. Cheng L, Zheng S, Raghunathan K, Priest DG, Willingham MC, Norris JS, Fan W (1995) Characterisation of Taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 2: 249-257
4. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356
5. De Brabender M, Geuens G, Nuydens R, Willebrords R, Aerts F, De Mey J (1996) Microtubule dynamics during the cell cycle: the effects of Taxol and nocodozole on the microtubule system of pt K2 cells at different stages of the mitotic cycle. In International Review of Cytology, Bourne GH, Danielli JF, Jeon KW (eds) pp 215-274. Orlando: Academic Press
6. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM (1997) DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 57: 1013-1019
7. Edelman MJ, Gandara DR (1996) Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 37: 385-393
8. Einzig AI, Wiernik PH (1995) Melanoma. In Paclitaxel in Cancer Treatment, McGuire WP, Rowinsky EK (eds) pp 321-327. New York: Marcel Dekker Inc
9. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS (1978) Biology of the human malignant lymphomas IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 42: 2379-2391
10. Epstein RJ, Watson JV, Smith PJ (1988) Subpopulation induced cell-cycle delay in human tumour cells using 90° light scatter. Cytometry 9: 349-358
11. Etlinger DS (1993) Overview of paclitaxel (Taxol) in advanced lung cancer. Semin Oncol 20: 46-49
12. Forastiere AA (1993) Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 20: 56-60
13. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC (2002) Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62: 2462-2467
14. Gong J, Traganos F, Darzynkiewicz Z (1995) Discrimination of G2 and mitotic cells by flow cytometry based on different expression of cyclins A and B1. Exp Cell Res 220: 226-231
15. Graniela Sire EA, Vikhanskaya F, Broggin M (1995) Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated, or no p53. Ann Oncol 6: 589-593
16. Holmes FA, Walters RS, Theriault AT, Forman AD, Newton LK, Raber MN, Buzdar AC, Fry DK, Hortobagyi GN (1991) Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805
17. Hortobagyi GN, Holmes (1996) Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 23 (1 Suppl 1): 4-9
18. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, schiff PB, Sorbana L, Zeheb R (1986) Taxol: mechanism of action and resistance. Ann NY Acad Sci 466: 733-744
19. Huizing MT, Keung ACF, Rosing H, van der Kuij V, Bokkel Huinink WW, Mandjes IN, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomised comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135
20. Jackman M, Firth M, Pines J (1995) Human cyclins B1 and B2 are localised to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J 14: 1646-1654
21. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556
22. Jordan MA, Wendell K, Gardiner S, Derry BW, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825
23. Juan G, Traganos F, Darzynkiewicz Z (2001) Methods to identify mitotic cells by flow cytometry. Methods Cell Biol 63: 343-354
24. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
25. Khan SH, Wahl GM (1998) P53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58: 396-401
26. Kluin-Nelemans HC, Limpens J, Meerabux J, Beverstock GC, Jansen JH, de Jong D, Kluin PM (1991) A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14, 18)(q32, q21). Leukemia 5: 221-224
27. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
28. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584
29. Lowe SW, Ruley HE, Jacks T, Housman DE (1993a) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
30. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993b) p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849
31. Manfredi JJ, Horwitz SB (1984) Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125
32. Manfredi JJ, Parness J, Horwitz SB (1982) Taxol binds to cellular microtubules. J Cell Biol 94: 688-696
33. Martinez-Exposito MJ, Kaplan KB, Copeland J, Sorger PK (1999) Retention of the Bub3 checkpoint protein on lagging chromosomes. Proc Natl Acad Sci USA 96: 8493-8498
34. Maxwell SA, Ames SK, Sawai ET, Decker GL, Cook RG, Butel JS (1991) Simian virus 40 large T antigen and p53 are microtubule associated proteins. Cell Growth Differ 2: 115-127
35. McGuire WP, Rowinsky EK, Rosenshine NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279
36. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumour effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314
37. Notterman D, Young S, Wainger B, Levine AJ (1998) Prevention of mammalian DNA reduplication following the release from mitotic spindle checkpoint requires p53 protein but not p53 mediated transcriptional activity. Oncogene 17: 2743-2751
38. Ormerod MG, Payne AWR, Watson JV (1987) Improved program for the analysis of DNA histograms. Cytometry 8: 637-641
39. cdc2. Cell 58: 833-846
40. Rao S, Horwitz SB, Ringel I (1992) Direct photoaffinity labelling of tubulin with Taxol. J Natl Cancer Inst 84: 785-788
41. Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr CA, Horwitz SB (1994) 3′-(p-azidobezamido)Taxol photolabels the N-terminal 31 amino acids of β-tubulin. J Biol Chem 269: 3132-3134
42. Roberts JR, Allison DC, Donehower RC, Rowinsky EK (1990) Development of polyploidization in taxol-resistant human leukaemia cells in vitro. Cancer Res 50: 710-716
43. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259
44. Rowinsky EK, Onnetto N, Cannetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumour agents. Semin Oncol 19: 646-662
45. Rowinsky EK, Tucker RW, Burke PJ, Ettinger D, Donehower RC (1989) Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 49: 4640-4647
46. Runowicz CD, Fields AL, Goldberg GL (1995) Promising new therapies in the treatment of advanced ovarian cancer. Cancer 76 (Suppl 10): 2028-2033
47. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by Taxol. Nature (London) 277: 665-667
48. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565
49. Schiff PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5-triphosphate or microtubule-associated proteins. Biochemistry 20: 3247-3252
50. Slichenmyer WJ, von Hoff DD (1991) Taxol: a new and effective anti-cancer drug. Anti-Cancer Drugs 2: 519-530
51. Smith PJ, Blunt N, Wiltshire M, Hoy T, Teesdale-Spittle P, Craven MR, Watson JV, Amos WB, Errington RJ, Patterson LH (2000a) Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe DRAQ5, in intact human cells analysed by flow cytometry, confocal and multiphoton microscopy. Cytometry 40: 280-291
52. Smith PJ, Rackstraw C, Cotter F (1994) DNA fragmentation as a consequence of cell cycle traverse in doxorubicin and idarubicin treated human lymphoma cells. Ann Haematol 69: 7-11
53. Smith PJ, Wiltshire M, Chin SF, Rabbits P, Soues S (2000b) Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells. Int J Radiat Biol 9: 1137-1147
54. 2+] transients correlation with cell cycle arrest and apoptosis in lymphoma cells. Am J Physiol-Cell Physiol 283: c609-c622
55. Sorger PK, Dobles M, Tournebize R, Hyman AA (1997) Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 9: 807-814
56. Taylor SS, Hussein D, Wang Y, Elderkin S, Morrow CJ (2001) Kinetochore localization and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. J Cell Sci 114: 4385-4395
57. Taylor SS, McKeon F (1997) Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 89: 727-735
58. Tishler RB, Lamppu DM, Park S, Price BD (1995) Microtubule-active drugs Taxol, vinblastine, and nocodozole increase the levels of transcriptionally active p53. Cancer Res 55: 6021-6025
59. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitisation to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79
60. Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628
61. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumour agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumour agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327
62. Watson JV, Chambers SH, Smith PJ (1987) A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry 8: 1-8
63. Widrow RJ, Rabinovitch PS, Cho K, Laird CD (1997) Separation of cells at different times within G2 and mitosis by cyclin B1 flow cytometry. Cytometry 27: 250-254
64. Wilson L, Bamburg JR, Mizel SB, Grisham LM, Cresswell KM (1974) Interaction of drugs with microtubule proteins. Fed Proc 33: 158-166
65. Wilson L, Jordan MA (1995) Microtubule dynamics: taking aim at a moving target. Chem Biol 2: 569-573
66. Wu GS, El-Deiry WS (1996) P53 and chemosensitivity. Nat Med 2: 225-226
67. Wyllie FS, Haughton MF, owson JM, Wynford-Thomas D (1999) Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. Br J Cancer 79: 1111-1120